|
1. 4. BenedictA, Arellano J, De Cock E, et al. Economic evaluation of duloxetine versusserotonin selective reuptake inhibitors and venlafaxine XR in treating majordepressive disorder in Scotland. J Affect Disord 2010; 120: 94-104 2. 5. ArmstrongEP, Malone DC, Haim Erder M. A Markov cost-utility analysis of escitalopram andduloxetine for the treatment of major depressive disorder. Curr Med Res Opin2008; 24: 1115-21 3. 6. WangPS, Patrick A, Azocar F, et al. The costs and benefits of enhanced depressioncare to employers. Arch Gen Psychiatry 2006; 63: 1345-53 4. 7. AzizM, Mehringer AM, Mozurkewich E, et al. Cost-utility of two maintenancetreatments for older adults with depression who responded to a course ofelectroconvulsive therapy: results from a decision analytic model. Can JPsychiatry 2005; 50: 389-97 |